Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETHANASH trial of microbial ethanol in NASH
NL-OMON48065Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2019
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of fomepizole, clindamycin, metronidazole and ciprofloxacin in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Peripheral plasma ethanol concentration during mixed meal test with and without fomepizole, Hepatic steatosis by liver ultrasonography and 6 more. Started May 2019; status: active, not recruiting.
02
Drugs
fomepizoleclindamycinmetronidazoleciprofloxacin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NL-OMON48065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48065.